Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesManagement of ankylosing spondylitis with infliximab
Open Access Rheumatology: Research and Reviews, 08/03/09
Toussirot E et al. – This review analyzes the available data on clinical, radiological, and biological efficacy of infliximab, the first anti-TNFα used in ankylosing spondylitis (AS), and discusses its place in the treatment of AS. Some questions persist, notably whether this treatment has disease-controlling properties.
- Data strongly supports that infliximab is highly effective in the treatment of AS pts
- Infliximab is effective in both spinal and peripheral manifestations, in sacroilitis or enthesitis, in reducing signs and symptoms of AS with an improvement of:
- All ASAS core set- disease activity, function, pain, stiffness, quality of life, and
- Laboratory parameters of inflammation or active inflammatory lesions detected on MRI
- Clinical response is retained for up to 5 yrs with maintenance therapy
- Global safety profile of infliximab seems favorable, but data are supported by a short-term use
- Long-term surveillance data begins to be available but more time is needed to know the safety for a longer period of time
- Currently, only a few cases of opportunistic infections have been reported in AS under infliximab and lymphoma is also a rare complicating situation
Related Articles
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research, 11/02/09
Relevance Score: 90%
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçets disease refractory to standard immunosuppressive drugs
Rheumatology International, 10/30/09
Relevance Score: 90%
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09
Relevance Score: 90%
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Relevance Score: 89%
Effects of home-based exercise program on the functional status and the quality of life in patients with rheumatoid arthritis: 1-year follow-up study
Rheumatology International, 11/17/09
Relevance Score: 84%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Taking the stress out of managing gout
Canadian Family Physician, 12/16/09
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis
Rheumatology International, 12/16/09
First-line DMARD choice in early rheumatoid arthritis - Do prognostic factors play a role?
Rheumatology, 12/15/09
Today in Spondylarthropathies...keeping you current
Receive free subspecialty "5-minute updates" via email
Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population
Rheumatology International, 12/16/09
Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-&alpha blocker therapy
Rheumatology, 12/15/09
Fetuin-A and interleukin-18 levels in ankylosing spondylitis
International Journal of Rheumatic Diseases, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor